STOCK TITAN
  1. Home
  2. News
  3. TLTFF

THERALASE TECHS INC - TLTFF STOCK NEWS

Welcome to our dedicated page for THERALASE TECHS news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on THERALASE TECHS stock.

Theralase Technologies Inc. (TLTFF) is a clinical stage pharmaceutical company dedicated to developing light and/or radiation activated small molecules for effectively destroying cancers, bacteria, and viruses. Their lead compound, RuvidarTM, has shown promise in inactivating various viruses and increasing efficacy in cancer cell destruction. Recent research has demonstrated RuvidarTM's ability to reverse the charge of BCG, creating a compound, RuBCG, with enhanced cancer cell kill rates. Additionally, Rutherrin® has proven effective in increasing chemotherapy efficacy and reducing multidrug resistance in cancer cells. Theralase is committed to advancing innovative therapies to combat challenging diseases and improve patient outcomes.

News

Theralase(R) Release's 1Q2024 Financial Statements

Rhea-AI Summary

Theralase Technologies, a clinical-stage pharmaceutical company, released its unaudited interim consolidated 1Q2024 financial statements. Key highlights include a 15% YoY revenue decline, with a gross margin of $62,114, down from $92,523 in 2023. Costs and expenses saw varied changes, with a notable 20% decrease in Drug Division R&D expenses to $725,017 and an 886% increase in Device Division R&D expenses to $31,363. Net loss reduced by 10% to $1,266,711.

Operationally, Theralase closed a $750,200 private placement and made significant progress in Study II, treating 68 patients, with a 63% complete response rate. Key updates on clinical data and Break Through Designation (BTD) submission to the FDA were also shared. The company aims for full patient enrollment in Study II by 2024 end, data lock by mid-2026, and FDA/Health Canada approval by late 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Theralase(R) Expands Clinical Team

Rhea-AI Summary

Theralase Technologies Inc. announces the addition of two Clinical Research Associates to its team to support the Phase II registration bladder cancer clinical study. The CRAs will facilitate the launch of new clinical study sites, patient enrollment, data review, ethics board approval, training, and Break Through Designation approval from the FDA. The company aims to commercialize RuvidarTM to provide a safe and effective treatment for bladder cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement

Rhea-AI Summary
Theralase(R) Technologies Inc. announces the successful closure of a $CAN 750,000 Non-Brokered Private Placement offering, issuing 4,167,778 Units at $CAN 0.18 per Unit. The funds will be used for advancing clinical studies, research, working capital, and general corporate purposes. The securities are not registered under the U.S. Securities Act and have a hold period until August 25th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Theralase(R) Granted Canadian Cancer Vaccine Patent

Rhea-AI Summary
Theralase Technologies Inc. receives a Canadian patent for a new cancer vaccine based on Photo Dynamic Compounds. The patent allows for the treatment of various cancers by inactivating cancer cells and programming the patient's immune system to destroy the cancer. Theralase's pipeline includes clinical studies for bladder, brain, and lung cancer, with plans to explore liquid cancers like leukemia and lymphoma. The company aims to secure financing for new clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
News

Theralase(R) Release's 4Q2023 Interim Financial Statements

Rhea-AI Summary
Theralase Technologies Inc. releases audited 2023 financial statements, hosting conference call to discuss results. Financial highlights show a 6% revenue decrease, gross margin decrease, decreased selling expenses, increased administrative expenses, and a 392% increase in stock-based compensation expense. Net loss decreased by 13%. Operational highlights include non-brokered private placements, Study II updates, Break Through Designation progress, and Study II preliminary clinical data showcasing positive results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none
-
News

Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association

Rhea-AI Summary
Theralase Technologies Inc. announces hosting of Advisory Board meetings to present Study II interim clinical data for Bacillus Calmette Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. The Company focuses on developing light activated Photo Dynamic Compounds for cancer treatment. The meetings will update Principal Investigators at the Canadian Urological Association and American Urology Association forums. Chief Scientific Officer highlights the potential of Ruvidar-based photodynamic therapy for patients with treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management conferences
News

Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease

Rhea-AI Summary
Theralase Technologies Inc. donates Theralase TLC-2400 Cool Laser Therapy systems to aid in Parkinson's Disease research at the University of Windsor. The collaboration aims to study the potential of CLT in treating Parkinson's, showcasing positive outcomes in preliminary studies and animal experiments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Rhea-AI Summary
Theralase Technologies Inc. announces the appointment of Dr. Michael Jewett as an independent consultant to assist in the completion of patient enrollment in the Phase II clinical study for the treatment of non-muscle invasive bladder cancer. The company aims to enroll 100 patients by the end of 2024 to potentially secure regulatory approval by 2027. Dr. Jewett's impressive background in surgical oncology and his advocacy for patient-centered care make him a valuable addition to the team. Theralase's photodynamic therapy technology has shown promising efficacy and safety profiles in treating BCG-Unresponsive NMIBC CIS, with high response rates and minimal side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement

Rhea-AI Summary
Theralase Technologies Inc. successfully closed a non-brokered private placement offering of units, issuing 6,666,670 units at a price of $CAN 0.18 per unit for gross proceeds of approximately $CAN 1,200,000. The company plans to use the proceeds for furthering the Phase II Non-Muscle Invasive Bladder Cancer clinical study, preclinical research and development of Rutherrin, working capital, and general corporate purposes. The offering is subject to a four-month hold period and final acceptance from the TSX Venture Exchange.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
none
News

Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study

Rhea-AI Summary
Theralase Technologies Inc. provides an update on its Phase II Non-Muscle Invasive Bladder Cancer clinical study, showcasing interim clinical data that exceeds International Bladder Cancer Group guidelines. The study demonstrates a complete response of 54% at 6 months, 38% at 12 months, and 37% at 15 months. Additionally, 62% of patients who received the optimized treatment achieved a complete response at 90 days, and 68% achieved a total response. The company has submitted a pre-Breakthrough Designation submission to the FDA and plans to complete enrollment and delivery of the primary study treatment for all patients in 2024, aiming for potential Health Canada and FDA approval by 2026 / 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial

FAQ

What is the current stock price of THERALASE TECHS (TLTFF)?

The current stock price of THERALASE TECHS (TLTFF) is $0.178 as of December 24, 2024.

What is the market cap of THERALASE TECHS (TLTFF)?

The market cap of THERALASE TECHS (TLTFF) is approximately 47.1M.

What is Theralase Technologies Inc. focused on?

Theralase is dedicated to developing light and/or radiation activated small molecules for effectively destroying various cancers, bacteria, and viruses.

What is RuvidarTM and its significance?

RuvidarTM is Theralase's lead compound, proven effective in inactivating viruses and increasing cancer cell destruction efficacy.

How does RuvidarTM impact BCG in cancer treatment?

RuvidarTM reverses the charge of BCG, creating RuBCG, which enhances cancer cell kill rates in bladder cancer therapy.

What is the role of Rutherrin® in chemotherapy?

Rutherrin® effectively increases chemotherapy efficacy and reduces multidrug resistance in cancer cells, offering potential in improving cancer treatment.

What is Theralase's commitment to innovation in healthcare?

Theralase is dedicated to advancing innovative therapies to combat challenging diseases, enhance treatment outcomes, and improve patient quality of life.

Stock TLTFF logo
THERALASE TECHS INC

OTC:TLTFF

TLTFF Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

TLTFF Stock Data

47.07M
203.72M
8.71%
Medical Devices
Healthcare
Link
United States of America
Toronto